Oligosaccharide Blocks PAR1 (Proteinase-Activated Receptor 1)-PAR4–Mediated Platelet Activation by Binding to Thrombin Exosite II and Impairs Thrombosis

Background: Inappropriate activation and aggregation of platelets can lead to arterial thrombosis. Thrombin is the most potent platelet agonist that activates human platelets via two PARs (proteinase-activated receptors), PAR1 and PAR4. The aim is to study the activity and mechanism of an oligosaccharide HS-11 (the undecasaccharide, derived from sea cucumber Holothuria fuscopunctata) in inhibiting thrombin-mediated platelet activation and aggregation and to evaluate its antithrombotic activity. Methods: Platelet activation was analyzed by detecting CD62P/P-selectin expression using flow cytometry. The HS-11-thrombin interaction and the binding site were studied by biolayer interferometry. Intracellular Ca2+ mobilization of platelets was measured by FLIPR Tetra System using Fluo-4 AM (Fluo-4 acetoxymethyl). Platelet aggregation, thrombus formation, and bleeding Assay were assessed. Results: An oligosaccharide HS-11, depolymerized from fucosylated glycosaminoglycan from sea cucumber Holothuria fuscopunctata blocks the interaction of thrombin with PAR1 and PAR4 complex by directly binding to thrombin exosite II, and completely inhibits platelet signal transduction, including intracellular Ca2+ mobilization and protein phosphorylation. Furthermore, HS-11 potently inhibits thrombin-PARs–mediated platelet aggregation and reduces thrombus formation in a model of ex vivo thrombosis. Conclusions: The study firstly report that the fucosylated glycosaminoglycan oligosaccharide has antiplatelet activity by binding to thrombin exosite II, and demonstrates that thrombin exosite II plays an important role in the simultaneous activation of PAR1 and PAR4, which may be a potential antithrombotic target for effective treatment of arterial thrombosis.

[1]  Wenqi Zheng,et al.  The components and activities analysis of a novel anticoagulant candidate dHG-5. , 2020, European journal of medicinal chemistry.

[2]  D. Newby,et al.  Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[3]  N. Mackman,et al.  Tissue factor in atherosclerosis and atherothrombosis. , 2020, Atherosclerosis.

[4]  Mark R Thomas,et al.  Novel antiplatelet targets in the treatment of acute coronary syndromes , 2020, Platelets.

[5]  Jinhua Zhao,et al.  Effects of Native Fucosylated Glycosaminoglycan, Its Depolymerized Derivatives on Intrinsic Factor Xase, Coagulation, Thrombosis, and Hemorrhagic Risk , 2020, Thrombosis and Haemostasis.

[6]  Longyan Zhao,et al.  From multi-target anticoagulants to DOACs, and intrinsic coagulation factor inhibitors. , 2019, Blood reviews.

[7]  K. Peter,et al.  Current and future antiplatelet therapies: emphasis on preserving haemostasis , 2018, Nature Reviews Cardiology.

[8]  D. Newby,et al.  PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[9]  J. Guay,et al.  Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding , 2017, Science Translational Medicine.

[10]  N. Sugimoto,et al.  Through-bond effects in the ternary complexes of thrombin sandwiched by two DNA aptamers , 2016, Nucleic acids research.

[11]  Sunil V. Rao,et al.  Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[12]  G. Raskob,et al.  Global Burden of Thrombosis: Epidemiologic Aspects. , 2016, Circulation research.

[13]  M. Nieman PARtitioning protease signaling. , 2015, Blood.

[14]  D. Angiolillo,et al.  Novel antiplatelet agents in acute coronary syndrome , 2015, Nature Reviews Cardiology.

[15]  M. Pavão Glycosaminoglycans analogs from marine invertebrates: structure, biological effects, and potential as new therapeutics , 2014, Front. Cell. Infect. Microbiol..

[16]  L. Faxälv,et al.  Thrombin-induced platelet activation via PAR4: pivotal role for exosite II , 2014, Thrombosis and Haemostasis.

[17]  J. Hamilton,et al.  Differential Signaling by Protease-Activated Receptors: Implications for Therapeutic Targeting , 2014, International journal of molecular sciences.

[18]  V. Pomin Holothurian Fucosylated Chondroitin Sulfate , 2014, Marine drugs.

[19]  Thomas H. Smith,et al.  Cofactoring and Dimerization of Proteinase-Activated Receptors , 2013, Pharmacological Reviews.

[20]  Marc P. Bonaca,et al.  Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.

[21]  Giuseppe Ambrosio,et al.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.

[22]  Ron O. Dror,et al.  High-resolution crystal structure of human Protease-Activated Receptor 1 bound to the antagonist vorapaxar , 2012, Nature.

[23]  S. Jackson Arterial thrombosis—insidious, unpredictable and deadly , 2011, Nature Medicine.

[24]  M. Hollenberg,et al.  Structure, function and pathophysiology of protease activated receptors. , 2011, Pharmacology & therapeutics.

[25]  E. Komives,et al.  Thermodynamic compensation upon binding to exosite 1 and the active site of thrombin. , 2011, Biochemistry.

[26]  A. Michelson Antiplatelet therapies for the treatment of cardiovascular disease , 2010, Nature Reviews Drug Discovery.

[27]  L. Jennings Role of platelets in atherothrombosis. , 2009, The American journal of cardiology.

[28]  N. Mackman Triggers, targets and treatments for thrombosis , 2008, Nature.

[29]  M. Bryckaert,et al.  Protease-activating Receptor-4 Induces Full Platelet Spreading on a Fibrinogen Matrix , 2007, Journal of Biological Chemistry.

[30]  E. Mammen,et al.  Tissue Factor , 2006, Seminars in thrombosis and hemostasis.

[31]  W. Bode,et al.  Structure and interaction modes of thrombin. , 2006, Blood cells, molecules & diseases.

[32]  E. Davie,et al.  An Overview of the Structure and Function of Thrombin , 2006, Seminars in thrombosis and hemostasis.

[33]  J. Huntington,et al.  Molecular recognition mechanisms of thrombin , 2005, Journal of thrombosis and haemostasis : JTH.

[34]  C. Esmon,et al.  Structure of the antithrombin–thrombin–heparin ternary complex reveals the antithrombotic mechanism of heparin , 2004, Nature Structural &Molecular Biology.

[35]  S. Olson,et al.  Binding of Exosite Ligands to Human Thrombin RE-EVALUATION OF ALLOSTERIC LINKAGE BETWEEN THROMBIN EXOSITES I AND II* , 2002 .

[36]  D. Leys,et al.  Atherothrombosis: A Major Health Burden , 2001, Cerebrovascular Diseases.

[37]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[38]  A. Kuliopulos,et al.  Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. , 2000, Biochemistry.

[39]  S. Coughlin,et al.  PAR3 is a cofactor for PAR4 activation by thrombin , 2000, Nature.

[40]  Z. Ruggeri,et al.  HEMOSTASIS , THROMBOSIS , AND VASCULAR BIOLOGY Contribution of Distinct Adhesive Interactions to Platelet Aggregation in Flowing Blood , 1999 .

[41]  E. Tremoli,et al.  Tissue factor in atherosclerosis. , 1999, Atherosclerosis.

[42]  S. Coughlin,et al.  Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. , 1999, The Journal of clinical investigation.

[43]  E. Braunwald,et al.  Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. , 1999, Journal of the American College of Cardiology.

[44]  Brian Savage,et al.  Specific Synergy of Multiple Substrate–Receptor Interactions in Platelet Thrombus Formation under Flow , 1998, Cell.

[45]  Robert V Farese,et al.  A dual thrombin receptor system for platelet activation , 1998, Nature.

[46]  J. Weitz,et al.  Evidence for Allosteric Linkage between Exosites 1 and 2 of Thrombin* , 1997, The Journal of Biological Chemistry.

[47]  V. Wheaton,et al.  Domains specifying thrombin–receptor interaction , 1991, Nature.

[48]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[49]  E. Lüscher,et al.  Actions of Thrombin and Other Coagulant and Proteolytic Enzymes on Blood Platelets , 1967, Nature.